熱門資訊> 正文
周六报道,iTeos Therapeutics宣布了葛兰素史克赞助的GALAXIES Lung-201 II期平台研究的后续中期数据,用于Belrestotug+Dostarlimab Doublet治疗既往未经治疗、不可切除、局部晚期或转移性PD-L1高非小细胞肺癌
2024-09-16 16:47
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose.
- >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy.
- Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations.
- GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。